Policy Prescriptions: User Fees, Biosimilars, Brexit
Executive Summary
US FDA extends its own user fee deadline; biosimilars earn a dubious milestone; and EMA unveils some contingency planning for Brexit. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet